Tesamorelin

Tesamorelin 2mg – Premium Growth Hormone Releasing Hormone (GHRH) Analogue for Visceral Fat Reduction & GH Stimulation Research | Targeted GHRH Analogue to Boost Natural GH Pulses, Reduce Abdominal Fat & Support Body Composition Optimization Insights

Target stubborn visceral fat with Tesamorelin 2mg from Ion Peptide, the high-purity synthetic Growth Hormone Releasing Hormone (GHRH) analogue designed for advanced laboratory studies on pituitary GH secretion, visceral adipose tissue reduction, IGF-1 elevation, and metabolic health. As a modified 44-amino acid GHRH analogue with a trans-3-hexenoyl group at the N-terminus, Tesamorelin stimulates the pituitary gland to release endogenous growth hormone in a natural, pulsatile manner — offering researchers a powerful, clinically relevant tool for investigating abdominal fat loss, lipid metabolism, and age-related body composition changes without significantly affecting other pituitary hormones.

Premium Product Overview

Tesamorelin (also known as TH9507) is supplied as a stable lyophilized acetate salt in convenient 2mg vials for easy reconstitution.

With the sequence trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂, molecular weight of approximately 5,135 Da, this modified GHRH analogue resists rapid enzymatic degradation for extended activity. Manufactured at ≥99% purity (third-party HPLC & MS verified), Tesamorelin 2mg provides researchers with a selective, potent tool for precise GH/IGF-1 axis and visceral fat pathway investigations.

Key Research Benefits of Tesamorelin 2mg

• Visceral Fat Reduction: Specifically targets and reduces deep abdominal (visceral) adipose tissue while preserving subcutaneous fat in research models.
• Natural Pulsatile GH Release: Stimulates physiologic GH pulses, elevating IGF-1 levels to support lean muscle preservation and metabolic function.
• Improved Body Composition: Promotes favorable shifts in waist circumference, lipid profiles, and overall fat distribution without broad anabolic effects.
• Metabolic Health Insights: Explored for benefits in lipid metabolism, insulin sensitivity, and age-related metabolic decline.
• Synergistic Potential: Frequently studied with growth hormone secretagogues (e.g., Ipamorelin, GHRP-2) for enhanced GH output and body composition outcomes.

Researchers value Tesamorelin as the “visceral fat specialist” GHRH analogue, offering targeted abdominal fat reduction with a clean GH stimulation profile.

Incorporate these naturally for better search engine performance on pages about Tesamorelin research, GHRH analogues, Tesamorelin for visceral fat studies, and premium research peptides for metabolic health.

Quality Assurance & Usage in Research

Sourced exclusively for laboratory research with USA-verified COAs. Tesamorelin 2mg reconstitutes easily with bacteriostatic water. Store lyophilized vials at -20°C and reconstituted solutions refrigerated.

Common Research Protocols (for reference only): Typical subcutaneous doses in studied models range from 1–2 mg once daily, often administered at bedtime to align with natural GH pulses. Some protocols explore 2 mg daily for 12–26 weeks. Always follow precise reconstitution and institutional guidelines.

Important Research Considerations

Tesamorelin 2mg is a potent research chemical intended strictly for laboratory use only. It was FDA-approved in specific formulations for reducing excess abdominal fat in HIV-associated lipodystrophy but remains a research-grade material in vial form for general experimental applications. Common observations include mild injection site reactions, joint pain, muscle aches, or transient glucose changes. It is not approved for general human therapeutic, cosmetic, or performance use. Prioritize proper protocols, biomarker monitoring (IGF-1 levels, waist circumference, lipid profiles), and consult qualified professionals for any application beyond strict lab research.